GLS1 (Glutaminase) inhibitor development

The GLS1 (glutaminase) project is part of an alliance between AstraZeneca and Cancer Research Technology to develop drugs targeting cancer metabolism. This poster gives a project overview on the lead finding and delivery of a series of novel cell active and orally bioavailable GLS1 inhibitors developed following a HTS screen of 900,000 compounds.

Poster presented by Mark Charles at AZ-Medimmune Cambridge Cancer Science Symposium (Cambridge, UK)

For reprints please contact: